From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma?

Cancer J. 2021 May-Jun;27(3):190-195. doi: 10.1097/PPO.0000000000000522.


High-dose therapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). With new treatment combinations offering the advantage of improved clinical outcomes of MM patients, the utilization of ASCT is again being addressed in the evolving treatment landscape. In this article, we review the role of frontline ASCT in the management of patients with MM.

Trial registration: NCT01208662 NCT04196491.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Multiple Myeloma* / drug therapy
  • Transplantation, Autologous

Associated data